Corporate ActionJun 4, 2026, 05:26 PM
NRx Pharmaceuticals Closes $22.3M Public Offering of Common Stock
AI Summary
NRx Pharmaceuticals, Inc. announced the closing of its underwritten public offering of common stock, raising approximately $22.3 million in gross proceeds. This amount includes the full exercise of the underwriters' option to purchase additional shares. The company intends to utilize the net proceeds from the offering for working capital and general corporate purposes to support its growth.
Key Highlights
- NRx Pharmaceuticals closed a public offering of common stock on June 4, 2026.
- The offering generated approximately $22.3 million in gross proceeds.
- The underwriters fully exercised their option to purchase additional shares.
- A total of 5,714,286 shares were offered at $3.50 per share.
- The company estimates net proceeds of approximately $18.8 million, or $21.6 million if the option was fully exercised.
- Net proceeds will be used for working capital and general corporate purposes.
- The company, directors, and executive officers agreed to a 60-day lock-up period.
Price Impact
More from NRXP